Newly diagnosed Ph+ and Ph-like clinical trials
| Trial . | Planned patients . | Ages . | Intervention . | Status . | Clinical trials . |
|---|---|---|---|---|---|
| Ph+ | |||||
| EsPhALL2017/ COG AALL1631 | 475 | 1-21 | Standard risk: imatinib with EsPhALL vs COG high-risk pre-B ALL backbone High risk: alloBMT with imatinib maintenance | Recruiting | NCT03007147 |
| EA9181 | 330 | 18-75 | Dasatinib or ponatinib/blinatumomab vs dasatinib or ponatinib/Hyper-CVAD | Recruiting | NCT04530565 |
| GIMEMA ALL2820 | 236 | 18+ | Ponatinib/blinatumomab vs imatinib/ chemotherapy | Recruiting | NCT04722848 |
| U Chicago | 25 | 18+ | Inotuzumab + dasatinib + steroid Induction | Recruiting | NCT04747912 |
| Ph-like | |||||
| COG AALL1131 | 22 | 1-31 | Dasatanib with chemotherapy for ABL-class fusions | Closed to accrual | NCT02883049 |
| COG AALL1521 | 171 | 1-21 | Ruxolitinib with chemotherapy for CRLF2 rearrangements and other JAK pathway alterations | Closed to accrual | NCT02723994 |
| Total Therapy XVII | 790 | 1-18 | Dasatinib: patients with Ph+ and those with ABL-class fusion Ruxolitinib: patients with activation of JAK/STAT signaling | Closed to accrual | NCT03117751 |
| UCCC 1920 | 15 | 18-39 | Ruxolitinib: patients with activation of JAK/STAT signaling | Recruiting | NCT03571321 |
| Trial . | Planned patients . | Ages . | Intervention . | Status . | Clinical trials . |
|---|---|---|---|---|---|
| Ph+ | |||||
| EsPhALL2017/ COG AALL1631 | 475 | 1-21 | Standard risk: imatinib with EsPhALL vs COG high-risk pre-B ALL backbone High risk: alloBMT with imatinib maintenance | Recruiting | NCT03007147 |
| EA9181 | 330 | 18-75 | Dasatinib or ponatinib/blinatumomab vs dasatinib or ponatinib/Hyper-CVAD | Recruiting | NCT04530565 |
| GIMEMA ALL2820 | 236 | 18+ | Ponatinib/blinatumomab vs imatinib/ chemotherapy | Recruiting | NCT04722848 |
| U Chicago | 25 | 18+ | Inotuzumab + dasatinib + steroid Induction | Recruiting | NCT04747912 |
| Ph-like | |||||
| COG AALL1131 | 22 | 1-31 | Dasatanib with chemotherapy for ABL-class fusions | Closed to accrual | NCT02883049 |
| COG AALL1521 | 171 | 1-21 | Ruxolitinib with chemotherapy for CRLF2 rearrangements and other JAK pathway alterations | Closed to accrual | NCT02723994 |
| Total Therapy XVII | 790 | 1-18 | Dasatinib: patients with Ph+ and those with ABL-class fusion Ruxolitinib: patients with activation of JAK/STAT signaling | Closed to accrual | NCT03117751 |
| UCCC 1920 | 15 | 18-39 | Ruxolitinib: patients with activation of JAK/STAT signaling | Recruiting | NCT03571321 |
alloBMT, allogeneic bone marrow transplantation.